Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
risperidone; quetiapine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| risperidone; quetiapine | DRUG | - |
Inclusion Criteria: * Subjects with bipolar I disorder in partial or full remission and deemed clinically stable Exclusion Criteria: * Current use of benzodiazepines, prescription or herbal sleep agents * Use of antihistamines * Use of antipsychotic medications in the past 6 months * Pregnant/bre...
Top 10 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 4 | PHASE3 | Xanomeline and trospium chloride, Xanomeline/Trospium Chloride |
| AbbVie, Inc. | ABBV | 3 | PHASE3 | Cariprazine, ABBV-932, Icalcaprant |
| Xenon Pharmaceuticals Inc. | XENE | 2 | PHASE3 | Azetukalner |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Rapport Therapeutics, Inc. | RAPP | 1 | PHASE2 | RAP-219 |
| Neurocrine Biosciences, Inc. | NBIX | 1 | PHASE2 | NBI-1117568 |
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-100 |
| LB Pharmaceuticals, Inc. | LBRX | 1 | PHASE2 | LB-102 |
| BioXcel Therapeutics, Inc. | BTAI | 1 | PHASE1 | BXCL501 |
| Alzamend Neuro, Inc. | ALZN | 1 | PHASE1 | AL001 |
Risperidone is an antipsychotic small molecule studied in bipolar disorder. It has been evaluated in a Phase 3 trial of stable bipolar I outpatients, where cognition was measured in relation to sedative effects. Johnson & Johnson is the developer associated with this program.
Quetiapine is an antipsychotic small molecule studied in bipolar disorder. It was compared with risperidone in a Phase 3 trial of stable bipolar I outpatients, focused on cognitive differences linked to sedative effects. Johnson & Johnson is the developer associated with this program.
Johnson & Johnson, which trades under the ticker JNJ, is the developer associated with the risperidone and quetiapine program in bipolar disorder. The company sponsored the Phase 3 trial that compared the two drugs in stable bipolar I outpatients.
Risperidone and quetiapine have been studied in a Phase 3 trial in bipolar disorder. That trial is completed, and no active trials for this program are listed. The drugs are investigational in this context and are not described as FDA approved for this use.
The risperidone and quetiapine program includes one completed Phase 3 trial, NCT00097032, titled Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients. It enrolled 30 participants aged 18 years and older and used a randomized, double-blind design.